| Glutamate-based antidepressants: 20 years on P Skolnick, P Popik, R Trullas Trends in pharmacological sciences 30 (11), 563-569, 2009 | 485 | 2009 |
| Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression P Skolnick, RT Layer, P Popik, G Nowak, IA Paul, R Trullas Pharmacopsychiatry 29 (01), 23-26, 1996 | 460 | 1996 |
| Adenosine A3 receptor stimulation and cerebral ischemia DKJE Von Lubitz, RCS Lin, P Popik, MF Carter, KA Jacobson European journal of pharmacology 263 (1-2), 59-67, 1994 | 355 | 1994 |
| Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. IA Paul, G Nowak, RT Layer, P Popik, P Skolnick The Journal of pharmacology and experimental therapeutics 269 (1), 95-102, 1994 | 343 | 1994 |
| Low doses of oxytocin facilitate social recognition in rats P Popik, J Vetulani, JM Van Ree Psychopharmacology 106 (1), 71-74, 1992 | 286 | 1992 |
| Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study M Siwek, D Dudek, IA Paul, M Sowa-Kućma, A Zięba, P Popik, A Pilc, ... Journal of affective disorders 118 (1-3), 187-195, 2009 | 272 | 2009 |
| 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug P Popik, RT Layer, P Skolnick Pharmacological Reviews 47 (2), 235-253, 1995 | 267 | 1995 |
| Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests IV Belozertseva, T Kos, P Popik, W Danysz, AY Bespalov European neuropsychopharmacology 17 (3), 172-179, 2007 | 226 | 2007 |
| Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor P Skolnick, P Popik, A Janowsky, B Beer, AS Lippa European Journal of Pharmacology 461 (2-3), 99-104, 2003 | 225 | 2003 |
| Laughing rats are optimistic R Rygula, H Pluta, P Popik PLoS One 7 (12), e51959, 2012 | 187 | 2012 |
| The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans A Bisaga, SD Comer, AS Ward, P Popik, HD Kleber, MW Fischman Psychopharmacology 157 (1), 1-10, 2001 | 183 | 2001 |
| Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715) RT Layer, P Popik, T Olds, P Skolnick Pharmacology Biochemistry and Behavior 52 (3), 621-627, 1995 | 169 | 1995 |
| Oxytocin but not vasopressin facilities social recognition following injection into the medial preoptic area of the rat brain P Popik, JM Van Ree European Neuropsychopharmacology 1 (4), 555-560, 1991 | 169 | 1991 |
| Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist P Popik, M Wrobel Neuropharmacology 43 (8), 1210-1217, 2002 | 163 | 2002 |
| In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists A Bisaga, P Popik Drug and alcohol dependence 59 (1), 1-15, 2000 | 162 | 2000 |
| Serum zinc level in depressed patients during zinc supplementation of imipramine treatment M Siwek, D Dudek, M Schlegel-Zawadzka, A Morawska, W Piekoszewski, ... Journal of affective disorders 126 (3), 447-452, 2010 | 160 | 2010 |
| Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models A Kłodzińska, E Chojnacka-Wojcik, A Pałucha, P Brański, P Popik, A Pilc Neuropharmacology 38 (12), 1831-1839, 1999 | 148 | 1999 |
| Trait pessimism predicts vulnerability to stress-induced anhedonia in rats R Rygula, J Papciak, P Popik Neuropsychopharmacology 38 (11), 2188-2196, 2013 | 147 | 2013 |
| NMDA antagonist properties of the putative antiaddictive drug, ibogaine. P Popik, RT Layer, LH Fossom, M Benveniste, B Geter-Douglass, ... The Journal of pharmacology and experimental therapeutics 275 (2), 753-760, 1995 | 146 | 1995 |
| Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine P Popik, W Danysz The Journal of pharmacology and experimental therapeutics 280 (2), 854-865, 1997 | 142 | 1997 |
agnieszka nikiforukInstitute of Pharmacology, Polish Academy of Sciences, Krakow, PolandVerified email at if-pan.krakow.pl
